Concordance of Pain Detection in Patients by Doloplus® and Algoplus® Behavioural Scales

NCT02174744 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 210

Last updated 2014-06-26

No results posted yet for this study

Summary

The pain of the elderly is often trivialized and ignored in spite of its high frequency: the chronic pain affects 50 % of the elderly living at home, 49 to 83 % of those living in institution and 80 % of this population at the end of life.

The evaluation of pain appeals to the same strategy as to the younger subject but with some specificities, related more to the pathologies associated with the ageing than to the real age. For that purpose, the investigators have self-assessment scales as the Numeric Pain Rating Scale which is adapted to estimate acute and chronic pains, but this scale presents a bias because, some patients do not express spontaneously their pain.

So behavioural scales were elaborated to solve the difficulties of detection and to care the pain of the elderly. The Algoplus® scale (5 items which takes less than one minute to be completed) whose objective is the observation of behavioural changes caused by the acute pain in elderly having communication disorders. The Doloplus® scale (30 items which allow in few minutes a good evaluation of pain) whose objective is the observation of behavioural changes caused by the chronic pain in elderly having communication impairments.

In practice, because of its popularity, the Algoplus® scale is widely used out of the specificity in which it has been validated. Practitioners, worried about this misuse, suggested to Doloplus® group, to test the concordance between the two behavioural scales in order to develop recommendations more targeted. The risk is that the use of the Algoplus® scale may underestimate pain that would have been detected by Doloplus® scale, and lead to under-treatment or non-treatment of pain in elderly having communication disorders.

This study aims to establish the concordance between these two scales to generate advices and recommendations to assess efficiently the pain in this vulnerable population.

The main objective of this study is to assess whether the use of Algoplus® scale is in good concordance with Doloplus® scale.

The secondary objective of this study is to assess the concordance with different levels of Algoplus® pain scale: (0-1), (2-3), (4-5).

Conditions

  • Pain in Elderly Patients Having Communication Disorders.

Interventions

OTHER

numeric pain rating scale

Sponsors & Collaborators

  • Dr. Gisèle PICKERING (MCU, PH) Center of clinical pharmacology/CIC Inserm-1405 - Main investigator - Coordinating center

    collaborator UNKNOWN
  • Ms Joëlle DEVOT - Collaborator

    collaborator UNKNOWN
  • Dr Patrice RAT - Investigator

    collaborator UNKNOWN
  • Dr Chandra COLOM - Investigator

    collaborator UNKNOWN
  • Mr Dieudonné ENDOUGOU - Collaborator

    collaborator UNKNOWN
  • Dr Cyril GUILLAUME - Investigator

    collaborator UNKNOWN
  • Ms Nathalie ROUX - Collaborator

    collaborator UNKNOWN
  • Dr Yves PASSADORI - Investigator

    collaborator UNKNOWN
  • Ms Nathalie DANNENBERGER - Collaborator

    collaborator UNKNOWN
  • Dr Micheline MICHEL - Investigator

    collaborator UNKNOWN
  • Dr Sylvie CHAPIRO- Investigator

    collaborator UNKNOWN
  • Dr Jean-François VILLARD - Investigator

    collaborator UNKNOWN
  • Dr Bernard WARY- Investigator

    collaborator UNKNOWN
  • Dr Anne-Cécile BOURJAL - Investigator

    collaborator UNKNOWN
  • Dr Catherine BLUNTZ - Investigator

    collaborator UNKNOWN
  • Dr Françoise CAPRIZ - Investigator

    collaborator UNKNOWN
  • Dr Marie FLOCCIA - Investigator

    collaborator UNKNOWN
  • Dr Jérôme BOHATIER - Investigator

    collaborator UNKNOWN
  • Ms Linh NGUYEN PHUONG - Collaborator

    collaborator UNKNOWN
  • University Hospital, Clermont-Ferrand

    lead OTHER

Principal Investigators

  • Gisèle PICKERING · University Hospital, Clermont-Ferrand

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-07-31
Completion
2014-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02174744 on ClinicalTrials.gov